Overview of Enabling Technologies in the Life Sciences. Professor Andrew Pitt, Aston University, Birmingham, UK

Similar documents
The National Institute of Genomic Medicine (INMEGEN) was

Genetics Lecture Notes Lectures 1 2

Clinical Research Infrastructure

Recombinant DNA and Biotechnology

Dr Alexander Henzing

CHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS

Human Genome and Human Genome Project. Louxin Zhang

AP Biology Essential Knowledge Student Diagnostic

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B

Integrating Bioinformatics, Medical Sciences and Drug Discovery

Transfection-Transfer of non-viral genetic material into eukaryotic cells. Infection/ Transduction- Transfer of viral genetic material into cells.

FACULTY OF MEDICAL SCIENCE

Microarray Technology

Structure and Function of DNA

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

M.Sc. in Nano Technology with specialisation in Nano Biotechnology

2019 Healthcare That Works for All

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298

European Medicines Agency

The Human Genome Project. From genome to health From human genome to other genomes and to gene function Structural Genomics initiative

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

INDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services

BIOSCIENCES COURSE TITLE AWARD

A leader in the development and application of information technology to prevent and treat disease.

Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources

Personalized medicine in China s healthcare system

Acceleration for Personalized Medicine Big Data Applications

BIOINF 525 Winter 2016 Foundations of Bioinformatics and Systems Biology

Name Class Date. Figure Which nucleotide in Figure 13 1 indicates the nucleic acid above is RNA? a. uracil c. cytosine b. guanine d.


Synthetic Biology for Global Health: A Problem-Driven Approach to Healthcare Innovation

Translation Study Guide

How To Change Medicine

Protein-responsive ribozyme switches in eukaryotic cells

Bachelor of Science in Applied Bioengineering

Activity 7.21 Transcription factors

Cystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program

Biochemistry Major Talk Welcome!!!!!!!!!!!!!!

Biotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15

Luca Romagnoli, Ph.D. Business Development Manager

Replication Study Guide

GENE CLONING AND RECOMBINANT DNA TECHNOLOGY

G E N OM I C S S E RV I C ES

Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research

Appendix 2 Molecular Biology Core Curriculum. Websites and Other Resources

The world of non-coding RNA. Espen Enerly


DOE Office of Biological & Environmental Research: Biofuels Strategic Plan

Health Informatics Research and Development in Europe

CCR Biology - Chapter 9 Practice Test - Summer 2012

Diabetes and Drug Development

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association

FACULTY OF MEDICAL SCIENCE

Nuevas tecnologías basadas en biomarcadores para oncología

Biotechnology: DNA Technology & Genomics

Bachelor of Science in Biochemistry and Molecular Biology

Module Catalogue. for the Master Degree Programme. Microbiology (M.Sc.)

Tanzania South Korea Joint Call for Research Proposals

Cancer Genomics: What Does It Mean for You?

13.2 Ribosomes & Protein Synthesis

Statement of ethical principles for biotechnology in Victoria

UNDERGRADUATE INTERNSHIP OPPORTUNITIES

ITT Advanced Medical Technologies - A Programmer's Overview

THE LINCOLN INSTITUTE OF HEALTH

How many of you have checked out the web site on protein-dna interactions?

Genetic Analysis. Phenotype analysis: biological-biochemical analysis. Genotype analysis: molecular and physical analysis

MDM. Metabolic Drift Mutations - Attenuation Technology

Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.

Masters Learning mode (Форма обучения)

University of Glasgow - Programme Structure Summary C1G MSc Bioinformatics, Polyomics and Systems Biology

Lecture 13: DNA Technology. DNA Sequencing. DNA Sequencing Genetic Markers - RFLPs polymerase chain reaction (PCR) products of biotechnology

INDUSTRY OVERVIEW LIFE SCIENCES RESEARCH PRODUCTS AND SERVICES. Overview

School of Nursing. Presented by Yvette Conley, PhD

OpenMedicine Foundation (OMF)

Genetics Module B, Anchor 3

Genetic diagnostics the gateway to personalized medicine

Human Genome Organization: An Update. Genome Organization: An Update

ATIP Avenir Program Applicant s guide

Basic Concepts of DNA, Proteins, Genes and Genomes

Year 10: The transmission of heritable characteristics from one generation to the next involves DNA

Biology Majors Information Session. Biology Advising Center NHB 2.606

How To Make Cancer A Clinical Sequencing

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

The 100,000 genomes project

Jeff Wolf Deputy Director HPC Innovation Center

Patent issues in Industrial Biotech:

Pharmacology skills for drug discovery. Why is pharmacology important?

White Paper. Yeast Systems Biology - Concepts

Research Strategy

Electronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider

A Perspective of Research on HLB and its Vector in the United States David G. Hall, Tim R. Gottwald and Calvin E. Arnold

Big Data Healthcare. Fei Wang Associate Professor Department of Computer Science and Engineering School of Engineering University of Connecticut

Curriculum Policy of the Graduate School of Agricultural Science, Graduate Program

Algorithms in Computational Biology (236522) spring 2007 Lecture #1

Hacking Brain Disease for a Cure

Coupling Engineering Sciences and Life Sciences: An overview of LAAS Activities with a special focus on Nano-Oncology Projects

Funding New Innovations in Synthetic Biology

Selvita Integrated drug discovery collaborations

Transcription:

Overview of Enabling Technologies in the Life Sciences Professor Andrew Pitt, Aston University, Birmingham, UK

Overview of Enabling Technologies in the Life Sciences Convergence Professor Andrew Pitt, Aston University, Birmingham, UK

Overview of Enabling Technologies in the Life Sciences Convergence of Biology and Chemistry...... and Engineering and Mathematics...... and Computer Science and Technology... Professor Andrew Pitt, Aston University, Birmingham, UK

Recent changes in perspective Fundamental changes in research drivers - Personalized medicine - Heterogeneity of disease one aetiology, many faces - Healthcare no longer the main driver Climate change and food security Energy Environment Global economy Changing disease demographics - Ageing populations: e.g. resurgence of neurosciences - Quality of life issues - Third world diseases becoming first world problem -Costs

Advances in technologies in the life sciences Moving on from the post-genomic era the new genomics era driven by new technology better awareness of biological complexity useful predictive models of biology systems biology Many more biological molecules now finding their way into the pharmaceutical arsenal use of biological agents to modulate biology a reality significant advances in the bulk production of biological agents advances in the delivery of biological agents (peptides, proteins, DNA) to biological systems (usually based on nanotechnology) Designer proteins and protein binding agents Effective protein engineering New detection technologies (e.g. peptide aptamers, SOMAmers, etc)

Advances in technologies in the life sciences Moving on from the post-genomic era the new genomics era driven by new technology better awareness of biological complexity useful predictive models of biology systems biology Many more biological molecules now finding their way into the pharmaceutical arsenal use of biological agents to modulate biology a reality significant advances in the bulk production of biological agents advances in the delivery of biological agents (peptides, proteins, DNA) to biological systems (usually based on nanotechnology) Designer proteins and protein binding agents Effective protein engineering New detection technologies (e.g. peptide aptamers, SOMAmers, etc)

Advances in technologies in the life sciences Common use of genetic modulation (targeting genes) - RNAi, sirna, stable transfection, gene therapy Rapid decrease in the cost and availability of synthetic oligonucleotides - Routine gene synthesis feasible genome synthesis Ability to effectively engineer biology - Synthetic biology Effective application of microengineering - miniaturization, portability (power), distributed networks (mobile phones) New approaches to understanding biology enabled by new technologies Systems biology, Functional genomics Deciphering of biological networks

Advances in technologies in the life sciences Common use of genetic modulation (individual genes) - RNAi, sirna, stable transfection, gene therapy Rapid decrease in the cost and availability of synthetic oligonucleotides - Routine gene synthesis feasible genome synthesis Ability to effectively engineer biology - Synthetic biology Effective application of microengineering - miniaturization, portability (power), distributed networks (mobile phones), diagnostics New approaches to understanding biology enabled by new technologies Systems biology, Functional genomics Deciphering of biological networks

Drive to identify biomarkers: a measurable indicator of a biological state Interleukin 6 homocysteine Molecular Physical Observational Genetic Focus on molecular biomarkers that can be used to characterize: normal biological processes pathogenic processes, especially early markers, diagnosis, prognosis specific responses to intervention Requires rapid, sensitive, multiplexed analysis and powerful statistics (Re)discovering that biology is much more heterogeneous than we thought

Drive to identify biomarkers: a measurable indicator of a biological state Interleukin 6 homocysteine Molecular Physical Observational Genetic Focus on molecular biomarkers that can be used to characterize: normal biological processes pathogenic processes, especially early markers, diagnosis, prognosis specific responses to intervention Requires rapid, sensitive, multiplexed analysis and powerful statistics (Re)discovering that biology is much more heterogeneous than we thought

Watchpoints Systems to Synthetic biology Genome sequencing and DNA synthesis Protein engineering Directed delivery systems for biological agents

Systems Biology Construction of predictive models of biology from molecules to ecosystems Enables rational engineering of biological systems (model: prediction: biological validation: refine) cycle complex and time consuming - identifies where models do not fit - leads to new discoveries. Developing enabling stochastic and multiscale modelling (molecule-cell-tissue-organ-organism-ecosystem) Enabled by data rich post-genomic technologies, high power computing, scientific collaboration, faster/cheaper biological data collection, www. analyze my data.com

We still don t have a full model 211 reactions and 322 components that take part in them 202 proteins, 3 ions, 21 small molecules, 73 oligomers, 7 genes, 7 RNAs but already providing biological insight Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H., Molecular Systems Biology 1:2005.0010

Computational power: distributed Computing Supercomputer power from low level computing Easy access to required hardware over internet GPUs particularly suited to many calculations Applicable to many complex computational problems Grid computing architectures Folding@home Cells@home POEM@home Rosetta@home. (>50 projects) Folding@home - 426,787 processors (Feb 2012) 6.588 petaflop/s (IBM Sequoia, 16.32 petaflop/s)

Synthetic Biology Generation of new biological entities by the engineering of organisms or intervention in biological processes Use non-biological molecules to generate life in vivo application of systems biology Enabled by DNA synthesis and delivery Understanding biological pathways and control systems Generation of cell-like self-assembling physical systems Computational modelling

Synthetic Biology huge potential suppressed a step in the pathway that allows yeast to make sterols from farnesyl pyrophosphate (FPP) added a gene from the wormwood plant itself, encoding the enzyme that converts FPP to amorphadiene. identified another enzyme from A. annua (P450 family) which oxidises amorphadiene to artemisinic acid "Engineering a mevalonate pathway in Escherichia coli for production of terpenoids," by Vincent J. J. Martin, Douglas J. Pitera, Sydnor T. Withers, Jack D. Newman, and Jay D. Keasling, Nature Biotechnology, 1 July 2003. Competitive with breeding programmes for Artemesia

Synthetic Biology Bacterium Genetic engineering Systems biology Synthetic biology Yeast Solar powered chemical plant Insect

Next generation Genomics Technologies Next-(next)-generation sequencing massively parallel, extremely rapid, high fidelity easy genomes Concomitant decreasing cost of DNA synthesis Easy access to DNA tools Genetic regulation Non-coding DNA and RNA Epigenetic information Small samples (single cell sampling) Can isolate small numbers of cells (LMD, FACS, etc) and now have sensitivity and speed to analyze whole (or parts of) cells Direct sampling without expansion (growth of bacteria, etc)

Genomics From GOLD: www.genomesonline.org

The new genomics revolution High throughput next generation sequencing has completely changed the landscape New breakthroughs offer real-time single molecule sequencing - reduce data collection time to hours The $1000 human genome is just round the corner

The new genomics revolution What does it provide? Rapid genotyping identification of organisms, personalized medicine (susceptibility genome wide association studies) Potential for phenotyping link to characteristics Rapid identification of pathogenicity factors e.g. virulence Understanding of biological paradigms, e.g. drug resistance Genetic manipulation; insertion/modulation of pathways cheap and easy Genome synthesis build a bug

Prediction of Protein Structure and Design of New Entities Many toxin structures available (>1400 toxins, mutants or toxin binding on RCSB) Mechanisms of action known for most Principles of protein structure prediction improving Proof of concept for chimeric toxins PA 63 The finding also points to a possible way to design anthrax toxin molecules that selectively attack tumor cells,. 2004 Leppla 2008

New biology does not make a drug or a weapon Ricin: weapon of choice? is this a battlefield? Nanomaterial and nanoparticle technologies for targeted delivery of chemical and biological agents Focus on smart delivery systems - many of these systems are self assembling (and disassembling) and can be made responsive to environment - transdermal and aerosol delivery - neurological targetting

When is Control Required/Justified? High level science openly available but is it enough in itself: is biology simple enough to manipulate easily? Only by dissemination can we get input of wider community and raise community awareness of dual use issues Validation/peer review is vital to identify relevance An open policy will allow us to stay ahead of the terrorists; including Nature How best to police the biology (e.g. DNA synthesis)

Watchpoints Systems to Synthetic biology Genome sequencing and DNA synthesis Protein engineering Directed delivery systems for biological agents